AVTX AVTX
Company Profile ↓Company Overview
AVTX (AVTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $59.00K (-86.6% YoY); net profit $-78.26M.
- Trailing 12 Months Year-on-year growth — revenue -86.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -61.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -61.19% |
| 1 Year: | -86.62% |
Stock Price Performance
| 1 Year: | +110.03% |
| 6 Months: | +18.05% |
| 3 Months: | +15.87% |
| 1 Month: | -2.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.10 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -61.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 384 | 157.80K | 25.04M | - | 4.48M | 4.79M | 4.07M | 2.58M | 1.39M | 2.20M | 2.75M | 1.34M | 1.11M | 473.00K | 3.35M | 1.35M | 1.17M | 1.03M | 14.95M | 475.00K | 643.00K | 236.00K | 0 | 0 | 249.00K | - | 0 | 0 | 0 | 59.00K | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 87.00K | 0 | 0 | 0 | 0 | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 105.00K | 0 | 0 | 0 | 59.00K | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.67M | 19.32M | 19.20M | 19.80M | 20.90M |
| Operating Income | - | -2.48M | -2.89M | -1.96M | - | -4.94M | -3.49M | -5.96M | - | -1.90M | -1.77M | 21.92M | - | -3.75M | -5.75M | -24.31M | -5.00M | -2.55M | -2.86M | -31.41M | -11.81M | -13.28M | -30.58M | -17.13M | -16.46M | -20.85M | -11.83M | 4.09M | -8.79M | -7.15M | -3.75M | -32.77M | -9.57M | -12.86M | - | -14.67M | -19.32M | -19.20M | -19.74M | -20.90M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.53M | -19.18M | -19.14M | -19.73M | -20.88M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.14M | -20.75M | -30.61M | -13.59M | -19.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.00K | 16.00K | 11.00K | 130.00K | 12.00K |
| Net Income | -2.52M | -3.24M | -2.91M | -692.00K | -3.65M | -5.14M | -3.52M | -6.17M | -1.64M | -1.96M | -1.80M | 18.72M | -3.09M | -3.88M | -6.01M | -24.60M | -7.45M | -6.22M | -4.02M | -21.12M | -13.28M | -13.46M | -30.68M | -17.11M | -17.39M | -22.05M | -12.99M | 3.19M | -9.96M | -8.19M | -5.23M | -121.29M | 98.46M | 23.04M | - | -13.15M | -20.77M | -30.62M | -13.72M | -19.63M |
| Diluted EPS | - | - | - | - | - | - | - | -0.70 | - | -0.19 | -0.14 | 0.52 | -0.11 | - | - | -0.71 | - | - | - | - | - | - | - | - | - | -2.35 | -1.38 | 0.34 | -204.00 | -140.73 | -26.83 | -141.14 | -14.07 | -2.83 | - | -1.25 | -1.92 | -2.19 | - | -0.98 |
| R&D Expense | 2.26M | 1.72M | 1.88M | 1.24M | 1.75M | 2.29M | 2.50M | 4.58M | 773.00K | 953.07K | 493.65K | 965.00K | 1.96M | 1.65M | 1.08M | - | 3.40M | - | - | - | - | - | 2.50M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 1.15M | 27.81M | 7.03M | 6.75M | 6.70M | 5.40M | 18.05M | 1.92M | 441.00K | 59.00K |
| Operating Income | -12.93M | -17.12M | -11.01M | -16.08M | 13.89M | -35.38M | -16.14M | -72.84M | -82.13M | -37.44M | -27.35M | -68.51M | -72.92M |
| Net Income | -13.05M | -16.06M | -10.49M | -16.47M | 11.87M | -40.05M | -16.07M | -63.50M | -84.38M | -41.66M | -31.54M | -35.13M | -78.26M |
| Diluted EPS | - | - | -4.71 | -1.87 | 0.42 | -1.20 | - | - | - | -1,063.00 | -113.58 | -20.91 | -5.84 |
| R&D Expense | 8.91M | 12.24M | 6.59M | 10.15M | 4.37M | 5.79M | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 12.32M | 21.66M | 5.77M | 42.81M | 70.25M | 36.11M | 43.76M | 80.21M | 33.37M | 20.99M | 150.73M | 116.46M |
| Total Equity | -11.38M | -17.85M | -26.33M | 13.08M | 207.00K | 27.86M | 20.91M | 21.00M | 24.56M | 23.08M | -10.91M | 7.30M | 133.03M | 83.05M |
| Cash & Equivalents | 9.52M | 3.42M | 11.74M | 21.16M | 5.13M | 2.47M | 10.65M | 3.61M | 18.92M | 54.59M | 13.17M | 7.42M | 134.55M | 15.86M |
| Long Term Debt | - | - | 5.31M | 2.35M | 0 | 0 | 14.33M | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 10.30M | 8.57M | 5.56M | 14.95M | 49.34M | 15.11M | 19.19M | 57.13M | 44.28M | 13.69M | 17.70M | 33.41M |
| Current Liabilities | - | - | 4.99M | 5.85M | 4.31M | 11.09M | 26.22M | 12.16M | 15.22M | 19.89M | 22.11M | 4.62M | 6.96M | 12.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -10.16M | -14.57M | 12.58M | -3.13M | -19.13M | -40.54M | - | -26.75M | -30.68M | -49.06M | -51.46M |
| Investing Cash Flow | - | - | -19.98K | -34.88K | -18.91M | 865.46K | -443.00K | 11.13M | - | -95.00K | -133.00K | 356.00K | -81.72M |
| Financing Cash Flow | - | - | 19.60M | -1.43M | 3.74M | 10.40M | 12.56M | 44.78M | - | -14.70M | 25.04M | 175.85M | 14.59M |
| Capital Expenditure | -29.27K | -19.50K | -19.98K | -34.88K | -23.32K | -564.41K | -262.01K | -63.00K | -113.00K | -95.00K | - | - | - |
| Free Cash Flow | - | - | -10.18M | -14.61M | 12.56M | -3.69M | -19.40M | -40.60M | - | -26.85M | -30.68M | -49.06M | -51.46M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -41.55M | -5.77M | 127.15M | -118.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -1,394.6% | 49.9% | -503.4% | -239.1% | -1,087.4% | -1,521.6% | -207.4% | -1,421.6% | -15,535.6% | -123,601.7% |
| Net Margin % | - | - | - | -1,428.6% | 42.7% | -569.9% | -238.1% | -947.9% | -1,563.1% | -230.8% | -1,639.5% | -7,965.8% | -132,642.4% |
| ROE % | 73.1% | 61.0% | -80.2% | -7,957.2% | 42.6% | -191.6% | -76.6% | -258.5% | -365.5% | 381.7% | -431.9% | -26.4% | -94.2% |
| ROCE % | - | -233.7% | -69.6% | -1,103.6% | 43.8% | -80.3% | -67.4% | -255.3% | -136.2% | -332.7% | -167.0% | -47.7% | -70.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVTX
Why Did AVTX Stock Surge 45% In Pre-Market Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQZTBsWHlKcHhuU3I0VU1tQzVqeHFSbHVDR2xRWTVKekZIM3ljM1ZlRVBLams4aUJrTDIwWTVOVGxtS3NsaTZldDNlYVRQa1N4N0NVT3hESnhhb3pGUmx6LTU3MDlQVHRsa0lyZjJnVE5ITktoN1Nhby16OWlOU28tMFpKV0F3WS1LeTR0WT…
AVTX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBZcFZMeUVWd1NVNjZnNlN3R1BrNC1oYlBsMVhCYzgwaDV6YkFseWVRbGdmbFJ3eUR5T1FuX0lkYlFwN0lmZE1JTkoyaWZ6Rm0wU0dHOHRQZ29wVGJnNVYwR0RhMTZaMkh4ZGZzZzE4d01QYU92UjVoZHFn?oc=5" target="_blank">AVT…
Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026 - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPaEZzYjBXbEdQaWRkbE16TG1FaTdlQ08yZFYwbW9wbWhvS09IWlI2a0lxWkVjejBWelZHLVc3ZDdzM2ZXaTFvY0dkcDQtWlpzdVNlSUljTExtZHluYVBPa0t1ODdLU3lYSmhYODIyVUw4dEh4dnNZVmVaa0VUVDZ6NHJ2dVRBR2REdGswVU…
BlackRock, Inc. Adds Avalo Therapeutics Inc (AVTX) Shares Despite 60,733% GF Value Overvaluation - GuruFocus
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPWUhKRTdRMWZtbTc5LTMyQWtVQklUajBoQzJZaUZ1R0dUY0QxbTlxeWNzUDJ1WWJPSnAtVV9IckRNQXpFUjZESFpKNlpyQ2NmQzVtNEhucHdOTjlqa0hIVUdpMlI5dWdOX242T0Q3YmtUTlAwWnFmQnJQMGU0M19ralRJcmMzVk4zdjJNYk…
$AVTX stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQajd5TlpsTTNHWDJnQjI0MzdRNHBmVE5EWmFac1VCZHk0N0k4dUFhWXhrdTNTcFJwM0xVdFI5SkxfZkZNUVlJN3MwMDUzUHdtWmdLXzBhci0xMmpZR1Y2cVZscHlMM1dwSXY2dWhDVWJTajM2b2d0YS1QVWY5OWgzMW5VUllzQTlrdWlfdl…
Avalo develops longer-lasting antibody to enable less frequent dosing - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPNE55YTc5Y2J3eXZlQ1BiUnhvVlVGdUFHU1RrQjBMSnBMNjdaSUZtRE83bWs3bzlEdFVzS3EzQVZDUUtUTWxTZW5uVU1NQzh1NGJuaUotOVdXT3pUMWtiZzQtcUhEUm5GWmY0TUZwMVh1NldqbVB6dmdzcWZYbnY2azI3T1IwUHFzNV8ycX…
AVTX — Frequently Asked Questions
What is the current share price of AVTX?
As of 2026-08-05 17:25 PDT, AVTX trades at $18.84 on NASDAQ/NYSE. Its 52-week range is $8.20 to $22.87.
What is the P/E ratio of AVTX?
AVTX trades at a trailing price-to-earnings (P/E) ratio of -3.23.
What is the return on equity (ROE) of AVTX?
AVTX has a return on equity (ROE) of -94.23%. Its return on capital employed (ROCE) is -70.45%.
Is AVTX a good stock to buy?
This page provides a data-driven analysis of AVTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.